Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

Bone resorption by osteoclasts is coupled with bone formation by osteoblasts, and this balanced process continuously remodels and adapts the skeleton. The receptor activator of nuclear factor kappaB ligand (RANKL) has been identified as an essential cytokine for the formation and activation of osteoclasts. The effects of RANKL are physiologically counterbalanced by the decoy receptor osteoprotegerin (OPG). Estrogen deficiency, glucocorticoid exposure, T-cell activation (eg, rheumatoid arthritis), and skeletal malignancies (eg, myeloma, metastases) enhance the ratio of RANKL to OPG and, thus, promote osteoclastogenesis, accelerate bone resorption, and induce bone loss. Moreover, alterations of the OPG/RANKL/RANK system have been implicated in vascular diseases. RANKL blockade (using OPG or RANK fusion proteins or RANKL antibodies) has prevented bone loss caused by osteoporosis, chronic inflammatory disorders, and malignant tumors in animal models and may emerge as a therapy in humans based on studies in postmenopausal osteoporosis, myeloma bone disease, and osteolytic metastases. This review summarizes the clinical implications of the OPG/RANKL/RANK system for bone and vascular diseases.

[1]  N. Sato,et al.  Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. , 2000, Biochemical and biophysical research communications.

[2]  F. Hamdy,et al.  Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.

[3]  W. Poewe,et al.  Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease , 2004, Circulation.

[4]  L. Hofbauer,et al.  RANK ligand and osteoprotegerin in myeloma bone disease. , 2003, Blood.

[5]  S. Cummings,et al.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. , 2001, The Journal of clinical endocrinology and metabolism.

[6]  J. Pike,et al.  Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Y. Ikari,et al.  Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002, Circulation.

[8]  S. Reddy,et al.  Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. , 2000, The Journal of clinical investigation.

[9]  Qingbo Xu,et al.  Soluble RANKL and risk of nontraumatic fracture. , 2004, JAMA.

[10]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  P. Price,et al.  Osteoprotegerin Inhibits Artery Calcification Induced by Warfarin and by Vitamin D , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[12]  D. Lacey,et al.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.

[13]  R. Bataille,et al.  Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. , 2001, Blood.

[14]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[15]  Steven W. Martin,et al.  A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases , 2003, Cancer.

[16]  Paul J. Williams,et al.  Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. , 2001, Cancer research.

[17]  T. Plesner,et al.  Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. , 2002, Blood.

[18]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[19]  P. Kostenuik,et al.  Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis , 2000, The Journal of experimental medicine.

[20]  L. Hofbauer,et al.  Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  R. Wallace,et al.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.

[22]  E. Clark,et al.  Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[23]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[24]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  K. Ozono,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. , 2001, Cancer research.

[26]  L. Joosten,et al.  IL-17 Promotes Bone Erosion in Murine Collagen-Induced Arthritis Through Loss of the Receptor Activator of NF-κB Ligand/Osteoprotegerin Balance 1 , 2003, The Journal of Immunology.

[27]  P. Mantyh,et al.  Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.

[28]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[29]  P. Kostenuik,et al.  Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Colin R Dunstan,et al.  A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[32]  A. Waage,et al.  Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. , 2001, Blood.

[33]  T. Martin,et al.  Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .

[34]  J. Penninger,et al.  Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. , 2000, The Journal of clinical investigation.

[35]  A. Berghold,et al.  Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. , 2003, Bone.

[36]  W. Maśliński,et al.  High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. , 2002, Arthritis and rheumatism.

[37]  R. Eastell,et al.  Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. , 2002, The Journal of clinical endocrinology and metabolism.

[38]  R. L. Cain,et al.  Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption , 2004, Journal of Pharmacology and Experimental Therapeutics.

[39]  B. Riggs,et al.  Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. , 2001, Biochemical and biophysical research communications.

[40]  L. Hofbauer,et al.  Increased osteoprotegerin serum levels in men with coronary artery disease. , 2003, The Journal of clinical endocrinology and metabolism.

[41]  B. L. Riggs,et al.  Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone , 2003, Journal of cellular biochemistry.

[42]  T. Nakashima,et al.  Force‐Induced Osteoclast Apoptosis In Vivo Is Accompanied by Elevation in Transforming Growth Factor β and Osteoprotegerin Expression , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  M. Whyte,et al.  Expansile Skeletal Hyperphosphatasia Is Caused by a 15‐Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  M. Podgornik,et al.  Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.

[45]  Hongtao Zhang,et al.  Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo* , 2004, Journal of Biological Chemistry.